IT Leaders May Underestimate the Risk of Shadow SaaS, Finds New Snow Software Survey
17.11.2022 17:00:00 EET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today unveiled new data highlighting the challenges facing IT leaders due to expanded software as a service (SaaS) usage. While a huge majority of IT leaders (96%) indicated they were ‘confident or very confident’ in their organization’s SaaS security measures, the top challenge for leaders managing SaaS was ‘employees adding new SaaS applications without notifying IT,’ suggesting that leaders may underestimate the importance of visibility in security.
According to IDC, SaaS is the top source for cloud spend in 2022, accounting for $177.8 billion of the market. In the new Snow survey examining the state of SaaS management, which surveyed 1,000 IT leaders from large organizations of 500+ employees in the United States and United Kingdom, 44% said ‘employees adding new SaaS applications without notifying IT’ is their top challenge to managing SaaS applications at their organization, closely followed by managing SaaS security (42%). When asked why these issues were so challenging, IT leaders indicated the impact to other IT programs (47%), organizational dynamics (38%), lack of time and resources (37%) and lack of visibility (36%).
“Post-pandemic IT teams are seeing a large increase in SaaS applications procured without the knowledge of IT,” said Becky Trevino, Executive Vice President of Products at Snow. “Amid increasing cybersecurity risks and mounting pressure to cut costs, IT leaders realize they need to better govern unknown and unsanctioned SaaS usage. CIOs are ultimately responsible for the security and management of SaaS applications regardless of where they are procured, and to do this effectively IT needs complete visibility into what it is they need to secure.”
Views on budget and security ownership depends on your leadership level
Cybersecurity is a major focus for IT decision-makers right now, particularly as business leaders navigate market uncertainty and plan 2023 budgets in anticipation of a recession. However, ownership is not clear among IT leaders, which can put organizations at risk for elevated costs and gaps in security.
- IT leaders ranked ‘managing the security of SaaS applications’ as the #1 most important issue to managing SaaS applications at their organization, followed by ‘identifying usage of all SaaS applications within our organization.’
- Ninety-six percent of those surveyed reported feeling ‘confident’ or ‘very confident’ in their organization’s SaaS security measures.
- According to the survey, SaaS purchasing power and IT/security responsibility rests firmly within two groups: CIOs/IT leadership and IT asset management (ITAM) or software asset management (SAM) teams.
- Senior leaders (41% of vice presidents, 45% of sr. vice presidents and 52% of C-level executives) look to the CIO and/or IT leadership to take responsibility for SaaS purchasing and security issues over other departments and roles, while more mid-level management (50% of managers and 44% of directors) put the onus of SaaS management and security on peers within ITAM/SAM.
- Forty-eight percent of IT leaders surveyed said that if budget, resources and time were not a factor, they’d like to pivot all SaaS application spending to IT to address SaaS sprawl.
Economic uncertainty is elevating cost concerns among IT leaders – though it’s not the top priority
Market conditions are driving increased scrutiny across all areas of cost in most organizations and optimizing spend while eliminating waste is an ongoing priority for IT teams. However, of those surveyed, IT leaders are currently more focused on cybersecurity of SaaS applications than costs.
- Despite continued uncertainty across the global markets, reining in the total cost of SaaS applications was ranked 5th on respondents’ priorities.
- If global uncertainty persists, more than three quarters of all respondents (77%) believe IT spend will decrease by as much as 50% to 75%.
- If IT spending decreases, IT leaders believe that the two core areas impacted will be IT staffing (20%) and strategic IT initiatives or programs (19%).
For more information about Snow’s latest survey, please visit: https://www.snowsoftware.com/blog/survey-anxiety-over-saas-security-plagues-it-leaders/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005232/en/
Contact information
Rachel Austin
Snow Software
press@snowsoftware.com
Taylor Donatell
PAN Communications
snow@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
